New Study Magnus Medical Administers SAINT Neuromodulation System for Major Depression Treatment to Initial Participants
Friday, July 21, 2023
Magnus Medical, a company specializing in medical devices and brain stimulation technology for neuropsychiatric conditions, recently announced the commencement of the Open Label Optimization (OLO) Clinical Trial. This trial aims to evaluate the efficacy of their Magnus Neuromodulation System with SAINT™ Technology in treating Major Depressive Disorder (MDD). Previous randomized controlled trials yielded promising results, with 79% of participants finding relief from severe depression after undergoing SAINT treatment. To address the pressing need for acute care in depression cases, the company intends to expand the availability of SAINT treatment while gathering more clinical data.
The OLO trial represents the first instance of studying the SAINT Neuromodulation System across multiple sites, facilitating the inclusion of a large sample of adults with clinical depression. This allows access to the rapid-acting, personalized treatment for those with treatment-resistant major depression. The study will involve up to nine clinics nationwide, enrolling around 1,000 adults who haven't experienced satisfactory improvement from prior antidepressant medications during their current episode of major depressive disorder. The treatment will be administered on an accelerated timeline, with 10 sessions per day, each consisting of 10-minute SAINT therapy sessions separated by 50-minute breaks, conducted over five consecutive days. The trial results are expected to be available in 2027.
Major Depressive Disorder (MDD), also known as clinical depression, is a severe form of depression characterized by persistent low mood and loss of interest in once enjoyable activities. Factors influencing MDD include genetics, stress, and brain chemistry. MDD is episodic and can last for months or even years.
The Magnus Neuromodulation System with SAINT™ Technology employs structural and functional magnetic resonance imaging (MRI) to inform a proprietary algorithm, enabling the identification of the optimal brain target for focused neurostimulation in individuals with MDD. This innovative approach is tailored to each person's brain connectivity and offers a significantly faster treatment timeline compared to conventional methods, which may take weeks or months to alleviate symptoms.